Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

International Regulators Agree On Foundations For Postmarket Clinical Studies

Executive Summary

A new document from the IMDRF outlines the conditions for when postmarket clinical follow-up studies may be necessary, but underscores they have to conform to their local regulatory regimes.

You may also be interested in...



Two Draft Guidances Set Up FDA’s Plans To Gather Postmarket Data

The guidance documents outline the statutory authority the US FDA has in requiring postmarket surveillance reports and studies, the real-world evidence it plans to ask for from sponsors, and administrative details that may be expected.

Verily’s Study Watch Rejected By FDA As Parkinson’s Drug-Development Tool

US regulators say Verily’s Study Watch – meant to be used in Parkinson’s trials – doesn’t collect data needed to assess whether a patient is truly benefitting from a drug.

FDA Says SBOMs Are Key To Better Cybersecurity In NIST Report

The US regulator’s report is meant to help develop new federal cybersecurity purchasing guidelines that could eventually be used to implement a cybersecurity consumer labeling program.

Topics

UsernamePublicRestriction

Register

MT143995

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel